Siirry sisältöön
Press Release_Lokon Pharma selects Biovian as a CDMO

Lokon Pharma AB signs an agreement with Biovian

Lokon Pharma AB, a company developing next-generation cancer therapeutics, has selected Biovian Oy as a CDMO partner for GMP manufacturing of LOAd703 for a pivotal randomized study. The uniquely engineered LOAd703 oncolytic virus is currently …